EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma

Chiharu Mizoguchi iD, Tadaaki Nishikawa iD, Hiroshi Yoshida iD, Masanori Yasuda iD, Tomoyasu Kato iD, Kosei Hasegawa iD, Kan Yonemori iD

Journal of Gynecologic Oncology · 2025

DOI: 10.3802/jgo.2025.36.e14 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Chiharu Mizoguchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinosarcoma, Erb-b2 Receptor Tyrosine Kinases, Uterine Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Uterine carcinosarcoma (UCS) is uncommon high-grade endometrial cancer with limited treatment options. We evaluated the prognostic significance of human epidermal growth factor receptor 2 (HER2) expression and HER2 gene amplification within large cohorts of UCS, and clarify clinicopathologic characteristics of HER2-low UCS. METHODS: We examined HER2 protein expression in 148 patients of UCS using in vivo diagnostic HER2 immunohistochemistry (IHC) kits and HER2 gene amplification using fluorescence in situ hybridization (FISH) in 72 patients. RESULTS: HER2 IHC score was evaluated according to the latest American Society of Clinical Oncology/College of American Pathologists criteria for gastric cancer, which was negative in 41 patients, low expression of 1+ was observed in 57 patients, and HER2 high expression was observed in 50 patients (2+ in 38 and 3+ in 12 patients). There was no significant statistical difference in clinicopathological characteristics based on HER2 protein expression status. HER2 negative and low expression compared to high expression revealed poor overall survival in stage I/ II. The concordance between IHC and FISH results were relatively low compared to other cancer types (HER2 IHC score 1+, 2+, and 3+ were 5%, 15%, and 50%), and combining these results was not efficient as a prognostic factor in UCS. In contrast, the HER2 IHC score alone was a prognostic factor in stage I/II UCS. HER2 low group did not show specific clinicopathologic features. CONCLUSION: Since the HER2 IHC score low in advanced UCS is a predictive factor, stratification of UCS using HER2 IHC score for HER2 IHC score low group and developing adjuvant therapy may be proposed in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinosarcomaErb-b2 Receptor Tyrosine KinasesUterine NeoplasmsHumansFemaleMiddle AgedAgedPrognosisIn Situ Hybridization, FluorescenceNeoplasm StagingImmunohistochemistryAged, 80 and overAdultGene AmplificationBiomarkers, Tumor

Stichwörter der Autor:innen

CarcinosarcomaERBB2 Protein, HumanImmunohistochemistryIn Situ HybridizationPrognosis

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. tnishika@ncc.go.jp.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Diagnostic Pathology, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.

ORCID-Profile: Chiharu Mizoguchi, Tadaaki Nishikawa, Hiroshi Yoshida, Masanori Yasuda, Tomoyasu Kato, Kosei Hasegawa, Kan Yonemori

Zitieren

APA

Mizoguchi, C., Nishikawa, T., Yoshida, H., Yasuda, M., Kato, T., Hasegawa, K., & Yonemori, K. (2025). HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e14

Vancouver

Mizoguchi C, Nishikawa T, Yoshida H, Yasuda M, Kato T, Hasegawa K, et al. HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e14

BibTeX
@article{Mizoguchi2025,
  author = {Mizoguchi, Chiharu and Nishikawa, Tadaaki and Yoshida, Hiroshi and Yasuda, Masanori and Kato, Tomoyasu and Hasegawa, Kosei and Yonemori, Kan},
  title = {HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  doi = {10.3802/jgo.2025.36.e14}
}
Kostenlos starten →